hVIVO (LON:HVO) Stock Price Down 6.8% – Should You Sell?

Shares of hVIVO plc (LON:HVO) were down 6.8% during mid-day trading on Friday . The company traded as low as GBX 19 ($0.24) and last traded at GBX 19.10 ($0.24). Approximately 2,518,262 shares changed hands during mid-day trading, a decline of 26% from the average daily volume of 3,389,765 shares. The stock had previously closed at GBX 20.50 ($0.25).

hVIVO Stock Down 0.4 %

The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The company has a market capitalization of £129.44 million, a P/E ratio of 634.17 and a beta of 0.97. The business’s fifty day moving average price is GBX 23.39 and its 200 day moving average price is GBX 26.71.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.